Cancer Drug "Oversized" Single-Dose Vials Waste Money, Need Rethinking – Article
This article was originally published in The Pink Sheet Daily
Amgen, Takeda and Merck push back against article’s conclusions on the waste generated by current vials for infused drugs.
You may also be interested in...
Manufacturers who sell single-use vials for products covered by Part B have about 16 months to consider pricing or packaging changes that may minimize exposure to a new refund for ‘wasted’ drug.
There may be significant savings from eliminating wasteful packaging for high cost specialty drugs. The US FDA, however, is urging policy makers not to overlook the importance of patient safety in packaging issues.
Medicare Part B spending on discarded, weight-based drugs sold in single-use vials is around $725m annually. The National Academies of Science, Engineering and Medicine is evaluating strategies to reduce the waste.